Market Share of Biologics CDMO Industry
The biologics contract development and manufacturing organization (CDMO) market is highly fragmented due to the presence of both global players and small and medium-sized enterprises. Some of the major players in the market are Boehringer Ingelheim Group, Wuxi Biologics (Cayman) Inc., Samsung Biologics, Lonza Group Ltd, and Fujifilm Diosynth Biotechnologies USA Inc. Players in the market are adopting strategies such as partnerships and acquisitions to enhance their product offerings and gain sustainable competitive advantage.
In March 2024, WuXi Biologics, a global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that it had broken ground on its 13.5-hectare CRDMO center in Tuas Biomedical Park in Singapore. The center will provide integrated biologics research and development along with manufacturing services. The CRDMO site also includes an additional 120,000L manufacturing capacity to WuXi Biologics’ global network.
In January 2024, Boehringer Ingelheim, the research-driven biopharmaceutical company, announced an expansion and upgrade of its plant in Koropi, Greece. The company announced an increase in the manufacturing capacity of new and existing medications that are in late-stage development, with an investment of EUR 120 million (USD 129.99 million).
Biologics Contract Development & Manufacturing Organization (CDMO) Market Leaders
-
Boehringer Ingelheim Group
-
Wuxi Biologics (Cayman) Inc.
-
Samsung Biologics
-
Lonza Group Ltd
-
Fujifilm Diosynth Biotechnologies USA Inc.
*Disclaimer: Major Players sorted in no particular order
-Market-Conc.webp)
